Gilead Expands Emergency Access to Experimental Coronavirus Drug
- Remdesivir given to over 1,000 patients for compassionate use
- Multiple clinical trials may report initial results in weeks
This article is for subscribers only.
We're tracking the latest on the coronavirus outbreak and the global response. Sign up here for our daily newsletter on what you need to know.
Gilead Sciences Inc. will expand access to its experimental anti-coronavirus drug remdesivir to accelerate its emergency use for multiple severely ill patients.